Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Yu Ho
Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Standard of care for glioblastoma (GBM) includes maximal safe resection followed by radiotherapy and temozolomide; however, recurrence often occurs, and further treatment is often hindered by the blood-brain barrier (BBB). Here, Fernandes et al.
The Effect of Simethicone Administration Timing and Pre-Examination Modified Position Changes on Defoaming Efficacy During Gastroscopy
This version is not peer-reviewed. Li Wen ,Liang Ruiru,Che Kakit,Yu Hon Ho * Li Wen ,Liang Ruiru,Che Kakit,Yu Hon Ho * Submitted: 02 December 2025 You are already at the latest version simethicone ; gastroscopy ; body position changes ; waiting time ; mucosal clarity ; defoaming efficacy This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing post-operative spatiotemporal blood-brain barrier disruption
Abstract Resection surgery is the first-line therapy for glioblastoma (GBM) that is performed in >70% of patients, typically within days of suspected diagnosis. Current protocols for follow-on chemoradiotherapy have shown only modest efficacy in eliminating residual disease, leading to inevitable tumour recurrence. There remains a need for new approaches to swiftly and effectively treat post-operative residual disease to prevent the rapid early progression of recurrent GBM.
Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Momelotinib is a recently approved inhibitor of Janus kinase 1 and 2 and activin A receptor type 1 for the treatment of myelofibrosis. While the in vitro drug–drug interaction (DDI) profile of momelotinib has been established, clinical evaluation of these results is needed. WHAT QUESTION DID THIS STUDY ADDRESS? Victim and perpetrator DDIs with momelotinib were characterized to guide clinical use. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease
Obesity and metabolic syndrome (MetS) are prevalent among chronic kidney disease (CKD) patients. However, it is unclear whether obesity without MetS is associated with a higher risk of adverse clinical outcomes in CKD patients. We searched the National Health Insurance Service database of Korea for patients who underwent national health screenings in 2009–2011 and identified 59 725 CKD patients. Obesity was defined as a body mass index ≥25 kg/m2.
How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease
Obesity and metabolic syndrome (MetS) are prevalent among chronic kidney disease (CKD) patients. However, it is unclear whether obesity without MetS is associated with a higher risk of adverse clinical outcomes in CKD patients. We searched the National Health Insurance Service database of Korea for patients who underwent national health screenings in 2009–11 and identified 59 725 CKD patients. Obesity was defined as a body mass index ≥25 kg/m2.
Regulation of the ATP‐binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood-brain barrier endothelial cells
GS–MF glutathione methylfluorescein PBEC porcine brain endothelial cell What is already known NR1I2 and NR1I3 up-regulate ABCB1 and ABCG2 transporter activity and protein expression in BBB. NR3C1 up-regulates ABCB1 and ABCG2 transporter activity and protein expression in BBB. What does this study add NR3C1 agonist up-regulates ABCC5 protein expression. NR1I3 agonist down-regulates ABCB1, ABCG2 and ABCC5 activity.
Corrigendum: Development and validation of urinary exosomal microRNA biomarkers for the diagnosis of acute rejection in kidney transplant recipients
In the published article, there was an error in the Funding statement. The funding statement for “National Research Foundation of Korea, funded by the Korean Government Ministry of Science and ICT (grant number 2018M3A9E8078807) should be changed to “Korean Health Technology R&D Project, Ministry of Health & Welfare (grant number HV22C019300)”. The correct Funding statement appears below.
Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study
Metabolic syndrome (MetS) is prevalent in patients with end-stage kidney disease, and kidney transplantation is expected to modify the metabolic status. However, whether changes in metabolic status at the time of transplantation affect recipient outcomes remains unclear. We analyzed 4187 recipients registered in a nationwide prospective cohort from 2014 to 2020. MetS was defined as the presence of three or more components of the metabolic syndrome.
Proteomic profiling of protein expression changes after 3 months-exercise in ESRD patients on hemodialysis
BMC Nephrology, Apr 2023 This is a preview of a remote PDF: https://bmcnephrol.biomedcentral.com/counter/pdf/10.1186/s12882-023-03146-w Jeong, Hye Yun, An, Hyun-Ju, Sung, Min Ji, Ha, Min Heui, Lee, Yu Ho, Yang, Dong Ho, Yang, Tae Young, Han, Dohyun, Lee, So-Young. , BMC Nephrology, 2023, pp. 1-10, Volume 24, Issue 1, DOI: 10.1186/s12882-023-03146-w
Proteomic profiling of protein expression changes after 3 months-exercise in ESRD patients on hemodialysis - BMC Nephrology
Study population This study prospectively enrolled ESRD patients in CHA bundang medical center in South Korea, and undergoing maintenance hemodialysis for at least 3 months was diagnostic criteria for ESRD. The overall scheme of this study is shown in Fig. 1. In September 2016, this study prospectively enrolled patients with end-stage renal disease (ESRD) treated with maintenance hemodialysis at the CHA Bundang Medical Center, South Korea.
Development and validation of urinary exosomal microRNA biomarkers for the diagnosis of acute rejection in kidney transplant recipients
Jung-Woo Seo1, 2, Yu Ho Lee3, Dong Hyun Tae4, Yang Gyun Kim1, Ju-Young Moon1, Su Woong Jung1, Jin Sug Kim1, Hyeon Seok Hwang1, Kyung-Hwan Jeong1, Hye Yun Jeong3, So-Young Lee3, Byung Ha Chung5, Chan-Duck Kim6, Jae Berm PARK7, Yeong Hoon Kim8, Junhee Seok4 and Sangho Lee1* 1Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Republic of Korea 2Research Laboratory, Medical Science Institute, Kyung Hee University Hospital at Gangdong, Republic of...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yu
Contact Yu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack